Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level study

View ORCID ProfileSnežana Medić, View ORCID ProfileCleo Anastassopoulou, Zagorka Lozanov-Crvenković, Vladimir Vuković, Nataša Dragnić, Vladimir Petrović, Mioljub Ristić, Tatjana Pustahija, Zoran Gojković, View ORCID ProfileAthanasios Tsakris, View ORCID ProfileJohn P. A. Ioannidis
doi: https://doi.org/10.1101/2022.04.08.22273571
Snežana Medić
1Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia
2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Snežana Medić
Cleo Anastassopoulou
3Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cleo Anastassopoulou
Zagorka Lozanov-Crvenković
4Department of Mathematics and Informatics, Faculty of Science, University of Novi Sad, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Vuković
1Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia
2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nataša Dragnić
5Center for Informatics and Biostatistics, Institute of Public Health of Vojvodina, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Petrović
1Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia
2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mioljub Ristić
1Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia
2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatjana Pustahija
1Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia
2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoran Gojković
2Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
6Clinical Center of Vojvodina, Novi Sad, Serbia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athanasios Tsakris
3Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Athanasios Tsakris
John P. A. Ioannidis
7Departments of Medicine, Epidemiology and Population Health, Biomedical Data Science, and Statistics, Stanford University, Stanford, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John P. A. Ioannidis
  • For correspondence: jioannid@stanford.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Data on the rate and severity of SARS-CoV-2 reinfections in real-world settings are scarce and the effects of vaccine boosters on reinfection risk are unknown.

Methods In a retrospective cohort study, registered SARS-CoV-2 laboratory-confirmed Vojvodina residents, between March 6, 2020 and October 31, 2021, were followed for reinfection ≥90 days after primary infection. Data were censored at the end of follow-up (January 31, 2022) or death. The reinfection risk was visualized with Kaplan-Meier plots. To examine the protective effect of vaccination, the subset of individuals with primary infection in 2020 (March 6-December 31) were matched (1:2) with controls without reinfection.

Findings Until January 31, 2022, 13,792 reinfections were recorded among 251,104 COVID-19 primary infections (5.49%). Most reinfections (86.8%) were recorded in January 2022. Reinfections were mostly mild (99.2%). Hospitalizations were uncommon (1.8% vs. 3.70% in primary infection) and COVID-19 deaths were very rare (n=20, case fatality rate 0.15%). The overall incidence rate of reinfections was 5.99 (95% CI 5.89-6.09) per 1,000 person-months. The reinfection risk was estimated as 0.76% at six months, 1.36% at nine months, 4.96% at 12 months, 16.7% at 15 months, and 18.9% at 18 months. Unvaccinated (OR=1.23; 95%CI=1.14-1.33), incompletely (OR=1.33; 95%CI=1.08-1.64) or completely vaccinated (OR=1.50; 95%CI=1.37-1.63), were modestly more likely to be reinfected compared with recipients of a third (booster) vaccine dose.

Interpretation SARS-CoV-2 reinfections were uncommon until the end of 2021 but became common with the advent of Omicron. Very few reinfections were severe. Boosters may modestly reduce reinfection risk.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Institute of Public Health of Vojvodina waived ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 22, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level study
Snežana Medić, Cleo Anastassopoulou, Zagorka Lozanov-Crvenković, Vladimir Vuković, Nataša Dragnić, Vladimir Petrović, Mioljub Ristić, Tatjana Pustahija, Zoran Gojković, Athanasios Tsakris, John P. A. Ioannidis
medRxiv 2022.04.08.22273571; doi: https://doi.org/10.1101/2022.04.08.22273571
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level study
Snežana Medić, Cleo Anastassopoulou, Zagorka Lozanov-Crvenković, Vladimir Vuković, Nataša Dragnić, Vladimir Petrović, Mioljub Ristić, Tatjana Pustahija, Zoran Gojković, Athanasios Tsakris, John P. A. Ioannidis
medRxiv 2022.04.08.22273571; doi: https://doi.org/10.1101/2022.04.08.22273571

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (553)
  • Anesthesia (135)
  • Cardiovascular Medicine (1761)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (660)
  • Epidemiology (10803)
  • Forensic Medicine (8)
  • Gastroenterology (592)
  • Genetic and Genomic Medicine (2952)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1930)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (631)
  • Infectious Diseases (except HIV/AIDS) (12520)
  • Intensive Care and Critical Care Medicine (693)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2801)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1469)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (867)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2641)
  • Public and Global Health (5374)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (596)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)